CD133 antigen expression in ovarian cancer

被引:74
|
作者
Ferrandina, Gabriella [1 ,2 ]
Martinelli, Enrica [1 ]
Petrillo, Marco [2 ]
Prisco, Maria Grazia [1 ]
Zannoni, Gianfranco [3 ]
Sioletic, Stefano [3 ]
Scambia, Giovanni [2 ]
机构
[1] Catholic Univ, Dept Oncol, Gynecol Oncol Unit, Campobasso, Italy
[2] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, I-00168 Rome, Italy
[3] Univ Cattolica Sacro Cuore, Inst Human Pathol, I-00168 Rome, Italy
来源
BMC CANCER | 2009年 / 9卷
关键词
TUMOR-INITIATING CELLS; STEM-CELLS; MARKER CD133; PROSPECTIVE IDENTIFICATION; MALIGNANT-MELANOMA; MESSENGER-RNA; CHEMORESISTANCE; GLIOBLASTOMA;
D O I
10.1186/1471-2407-9-221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Much attention has been recently focused on the role of cancer stem cells (CSCs) in the initiation and progression of solid malignancies. Since CSCs are able to proliferate and self-renew extensively, thus sustaining tumor growth, the identification of CSCs through their antigenic profile might have relevant clinical implications. In this context, CD133 antigen has proved to be a marker of tumor cells with stemness features in several human malignancies. The aim of the study was to investigate the clinical role of the immunohistochemically assessed expression of CD133 in a large single Institution series of ovarian cancer patients. Methods: The study included 160 cases admitted to the Gynecologic Oncology Unit, Catholic University of Campobasso and Rome. CD133 antigen was identified by the monoclonal mouse anti-CD133-1 antibody (clone CD133 Miltenyi biotec). Results: In the overall series CD133 positive tumor cells were observed in 50/160 (31.2%) cases. A diffuse cytoplasmic pattern was identified in 30/50 (60.0%), while an apical cytoplasmic pattern was found in 20/50 (40.0%) of CD133 positive tumors. As of September 2008, the median follow up was 37 months (range: 2-112). During the follow up period, progression and death of disease were observed in 123 (76.9%), and 88 (55.0%) cases, respectively. There was no difference in TTP between cases with negative (median TTP = 23 months) versus positive CD133 expression (median TTP = 24 months) (p value = 0.3). Similar results were obtained for OS. When considering the TTP and OS curves according to the pattern of CD133 expression, a trend to a worse prognosis for cases with diffuse cytoplasmic versus the apical cytoplasmic pattern was documented, although the statistical significance was not reached. Conclusion: The immunohistochemical assessment of CD133 expression seems not to provide additional prognostic information in ovarian cancer patients. The role of the different pattern of CD133 immunoreaction deserves further investigation in a larger series.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] CD133 antigen expression in ovarian cancer
    Gabriella Ferrandina
    Enrica Martinelli
    Marco Petrillo
    Maria Grazia Prisco
    Gianfranco Zannoni
    Stefano Sioletic
    Giovanni Scambia
    [J]. BMC Cancer, 9
  • [2] CD133 expression associated with poor prognosis in ovarian cancer
    Zhang, Jing
    Guo, Xiaoqing
    Chang, Doo Young
    Rosen, Daniel G.
    Mercado-Uribe, Imelda
    Liu, Jinsong
    [J]. MODERN PATHOLOGY, 2012, 25 (03) : 456 - 464
  • [3] Targeting CD133 antigen in cancer
    Ferrandina, Gabriella
    Petrillo, Marco
    Bonanno, Giuseppina
    Scambia, Giovanni
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (07) : 823 - 837
  • [4] Expression of CD133 and CD44 in serous ovarian cancer and peritoneal metastasis
    Stemberger-Papic, S.
    Vrdoljak-Mozetic, D.
    Ostojic, D. Versa
    Rubesa-Mihaljevic, R.
    Dinter, M.
    Eminovic, S.
    [J]. VIRCHOWS ARCHIV, 2017, 471 : S95 - S95
  • [5] Expression of Nestin and CD133 in serous ovarian carcinoma
    Onisim, Andrea
    Iancu, Mihaela
    Vlad, Catalin
    Kubelac, Paul
    Fetica, Bogdan
    Fulop, Annamaria
    Achimas-Cadariu, Andrei
    Achimas-Cadariu, Patriciu
    [J]. JOURNAL OF BUON, 2016, 21 (05): : 1168 - 1175
  • [6] CHANGES OF CD133 AND CD44 IN OVARIAN CANCER
    Fan, Zhongyan
    Chen, Longhua
    Wang, Zhaojuan
    [J]. ACTA MEDICA MEDITERRANEA, 2020, 36 (05): : 2993 - 2997
  • [7] CD133 AND CXCR4 EXPRESSION IN OVARIAN CANCER CELL LINEs
    Cioffi, M.
    Camerlingo, R.
    Consales, C.
    D'Alterio, C.
    Greggi, S.
    Pignata, S.
    Castello, G.
    Pirozzi, G.
    Scala, S.
    [J]. CYTOMETRY PART A, 2010, 77A (02) : 194 - 194
  • [8] Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells
    Kryczek, Ilona
    Liu, Suling
    Roh, Michael
    Vatan, Linhua
    Szeliga, Wojciech
    Wei, Shuang
    Banerjee, Mousumi
    Mao, Yujun
    Kotarski, Jan
    Wicha, Max S.
    Liu, Rebecca
    Zou, Weiping
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (01) : 29 - 39
  • [9] Expression of CD133 as a Biomarker in Pancreatic Cancer
    Hirano, K.
    Shibuya, K.
    Watanabe, T.
    Sawada, S.
    Yoshioka, I.
    Fujii, T.
    [J]. PANCREAS, 2019, 48 (10) : 1442 - 1443
  • [10] Epigenetic regulation of CD133 and tumorigenicity of CD133+ovarian cancer cells
    Baba, T.
    Convery, P. A.
    Matsumura, N.
    Whitaker, R. S.
    Kondoh, E.
    Perry, T.
    Huang, Z.
    Bentley, R. C.
    Mori, S.
    Fujii, S.
    Marks, J. R.
    Berchuck, A.
    Murphy, S. K.
    [J]. ONCOGENE, 2009, 28 (02) : 209 - 218